VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Novel targets and combinations being explored in MPNs

In this video, Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives an overview of novel targets and combination approaches being explored in myeloproliferative neoplasms (MPNs). Prof. Harrison highlights the promise of novel JAK inhibitors, such as momelotinib, and MDM2 inhibitors, including navtemadlin, and the importance of better understanding how to combine and implement these agents in clinical practice. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter